Holen Sie sich die Stockscreener-App
11.49
4.26%
0.47
Handel nachbörslich:
11.49
Enanta Pharmaceuticals Inc Aktie (ENTA) Neueste Nachrichten
How Enanta Pharmaceuticals Inc. stock performs in rising dollar environmentTrade Risk Report & Low Drawdown Trading Techniques - newser.com
Why Enanta Pharmaceuticals Inc. stock is rated strong buyJuly 2025 Update & Fast Entry High Yield Tips - newser.com
How Enanta Pharmaceuticals Inc. stock compares to growth peers2025 Key Lessons & Detailed Earnings Play Alerts - newser.com
Enanta pharmaceuticals prices $65M common stock offering - MSN
Chart based analysis of Enanta Pharmaceuticals Inc. trendsJuly 2025 Intraday Action & Daily Profit Focused Screening - newser.com
Why Enanta Pharmaceuticals Inc. stock is seen as undervalued2025 Institutional Moves & Fast Momentum Stock Entry Tips - newser.com
Published on: 2025-10-10 06:04:18 - newser.com
Using economic indicators to assess Enanta Pharmaceuticals Inc. potentialJuly 2025 Technicals & Technical Pattern Alert System - newser.com
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
What high frequency data says about Enanta Pharmaceuticals Inc.Quarterly Market Review & Fast Gain Swing Alerts - newser.com
Enanta Pharmaceuticals' (ENTA) "Sell (D-)" Rating Reiterated at Weiss Ratings - MarketBeat
Does Enanta Pharmaceuticals Inc. show high probability of rebound2025 Growth vs Value & Fast Exit and Entry Strategy Plans - newser.com
Is Enanta Pharmaceuticals Inc a good long term investmentGap Fill Strategies & Individual Stock Tracking Service - earlytimes.in
Enanta Pharmaceuticals to Present Data for Zelicapavir and EDP-323, Two Candidates in Development fo - PharmiWeb.com
Enanta Pharmaceuticals to Present Data for Zelicapavir and EDP-323, Two Candidates in Development for the Treatment of Respiratory Syncytial Virus (RSV) at IDWeek 2025 - Business Wire
Backtesting results for Enanta Pharmaceuticals Inc. trading strategies2025 Key Lessons & Risk Controlled Stock Alerts - newser.com
What’s next for Enanta Pharmaceuticals Inc. stock priceJuly 2025 Closing Moves & Stepwise Entry and Exit Trade Signals - newser.com
Quantitative breakdown of Enanta Pharmaceuticals Inc. recent moveWeekly Stock Report & Short-Term High Return Ideas - newser.com
Will Enanta Pharmaceuticals Inc. stock benefit from AI adoptionAnalyst Downgrade & Expert Curated Trade Setups - newser.com
Is Enanta Pharmaceuticals Inc. (9EP) stock a buy during volatile markets2025 Market Sentiment & Fast Entry High Yield Tips - newser.com
What Fibonacci levels say about Enanta Pharmaceuticals Inc. reboundJuly 2025 Momentum & Consistent Profit Alerts - newser.com
Is Enanta Pharmaceuticals Inc. (9EP) stock bottoming after sell offJobs Report & Daily Momentum Trading Reports - newser.com
Why Enanta Pharmaceuticals Inc. (9EP) stock gets analyst attention2025 Market Sentiment & Reliable Intraday Trade Alerts - newser.com
What’s the recovery path for long term holders of Enanta Pharmaceuticals Inc.Market Sentiment Report & Safe Swing Trade Setups - newser.com
Real time alert setup for Enanta Pharmaceuticals Inc. performanceJuly 2025 Opening Moves & Free Weekly Chart Analysis and Trade Guides - newser.com
What analysts say about Enanta Pharmaceuticals Inc 9EP stockRisk Management Strategies & Minimal Risk High Reward - earlytimes.in
Foley Hoag Advises Enanta Pharmaceuticals on $74.8 Million Upsized Public Offering - Foley Hoag
Enanta upgraded to buy at Jefferies on promise of RSV antiviral zalicapavir - MSN
Enanta Pharmaceuticals (ENTA) Is Up 33.3% After Positive Phase 2b RSV Results Propel Zelicapavir Forward - Sahm
Is Enanta Pharmaceuticals Inc. stock entering bullish territory2025 Geopolitical Influence & Smart Money Movement Tracker - newser.com
Enanta Pharmaceuticals Announces Closing of Upsized Public Offering of Common Stock, Including Full - PharmiWeb.com
Enanta Pharmaceuticals raises $74.75 million in public offering By Investing.com - Investing.com Canada
Enanta Pharmaceuticals raises $74.75 million in public offering - Investing.com
Enanta Pharmaceuticals announces closing of upsized public offering of common stock - MarketScreener
Enanta Pharmaceuticals Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares - FinancialContent
Enanta Pharmaceuticals falls on public offering of common stock - MSN
FY2027 Earnings Estimate for ENTA Issued By Leerink Partnrs - MarketBeat
Enanta Pharmaceuticals Announces Public Stock Offering - TipRanks
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):